**August 31, 2019**

**New frontiers: SGLT2 inhibitors in cardiorenal disease**
*Reykjavik - Village 2*

**Sat 31 Aug, 11:00 - 12:30**, Anti-Diabetic Pharmacotherapy, Advances in Science
Chairpersons: Stephen Wiviott, Mikhail Kosiborod

11:00: State of the Art - SGLT2 inhibitors in cardiovascular disease, Marc Sabatine
11:18: Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58, Thomas Zelniker

**Experts on the spot: expanding knowledge on glucagon-like peptide-1 receptor agonists in cardiometabolic care**
*Duras - The Hub*

**Sat 31 Aug, 12:45 - 13:15**, Cardiovascular Disease in Special Populations, Satellite Symposium - Experts on the Spot
Chairperson: Erin Bohula
12:45: Glucagon-like peptide-1 receptor agonist treatment landscape: highlighting the benefits of cardiovascular risk reduction, Erin Bohula
13:00: The future of cardiometabolic care: the impact of glucagon-like peptide-1 receptor agonists, Benjamin Morgan Scirica

**The right glucose-lowering drugs for the right patient**
*Reykjavik - Village 2*


14:37 Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus, David Berg

**Perspectives on anticoagulation across cardiovascular disease**
*Agora 1 - Poster Area*

**Sat 31 Aug, 13:45 – 15:00**, Anticoagulants, Rapid Fire Abstracts, Abstract-based Programme

14:50 Edoxaban versus warfarin in atrial fibrillation patients with low, mid and high body weight: analysis of outcomes in the ENGAGE-AF TIMI 48 trial, Giuseppe Boriani

**PCSK9i, changing practice in cardiology: the emerging story**
*Tbilisi - Village 6*

**Sat 31 Aug, 15:30 - 16:30**, Risk Factors and Prevention, Satellite Symposium
15:50: Extending the evidence: what did the FOURIER trial learns us on managing high risk patients?, Marc Sabatine

**September 01, 2019**

**Treatment of conundrum in acute heart failure**
*Sarajevo - Village 5*

**Sun 01 Sep, 08:30 - 10:00**, Acute Heart Failure, Advances in Science
09:42: Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial., David Morrow

**Eugene Braunwald and ESC Women in cardiology**
*ESC TV Stage - ESC Plaza*

**Sun 01 Sep, 12:45 - 13:15**, European Society of Cardiology - Other, Interview
12:45: Eugene Braunwald and ESC Women in cardiology., Eugene Braunwald
September 02, 2019

Poster Session 4: Advanced heart failure  
**Mon 02 Sep, 08:30 - 12:30**, Poster Session, Abstract-based Programme
08:30: Heart Failure hospitalization and mortality in non-valvular Atrial Fibrillation: The ENGAGE-AF TIMI 48 Trial, Riccardo Maria INCIARDI

Expert Advice - Best practice in acute coronary syndromes  
**Mon 02 Sep, 11:00 - 12:30**, Acute Coronary Syndromes – Treatment, Focus with the Experts
Chairpersons: Catherine KELLS, Eugene BRAUNWALD

The role of cardiac biomarkers to aid in diagnosis and risk stratification of cardiac diseases  
**Mon 02 Sep, 13:00 - 14:00**, Acute Heart Failure, Satellite Symposium
13:15: ENGAGE-AF, the role of blood-based biomarkers for the risk-prediction of atrial fibrillation patients as part of the ABC risk scores, David MORROW

Anticoagulation in the aging atrial fibrillation population - Perspectives from clinical trials and routine daily practice  
**Mon 02 Sep, 13:00 - 14:00**, Atrial Fibrillation, Satellite Symposium
13:20: Risks and benefits of anticoagulation in the elderly - Insights from randomized trials, Robert P GIUGLIANO

The north face in acute coronary syndromes: let’s climb it!  
**Mon 02 Sep, 13:00 - 14:00**, Acute Coronary Syndromes, Satellite Symposium
Chairperson: Marc SABATINE
13:00: LDL-C treatment after acute coronary syndromes: a fresh perspective, Marc SABATINE
13:30: The future is now, Marc SABATINE, Konstantinos KOSKINAS

Poster Session 5: Acute coronary syndrome treatment  
**Mon 02 Sep, 14:00 – 18:00**, Lipids, Special Session
14:00: Comparing biomarker profiles in patients with stable atherosclerosis treated with anacetrapib versus placebo: a nested proteomic study from HPS3/TIMI 55-REVEAL, David BERG

Professor Braunwald’s perspective on lipid lowering  
**Mon 02 Sep, 14:30 - 15:15**, Poster Session, Abstract-based Programme
14:00: What is the right age to start lipid lowering therapy, Eugene BRAUNWALD

Progress in secondary prevention - New treatments  
**Mon 02 Sep, 14:30 - 15:40**, Risk Factors and Prevention, Abstract Session
Chairpersons: Furio COLIVICCHI, Marc SABATINE

The north face in acute coronary syndromes: let’s climb it!  
**Mon 02 Sep, 16:00 - 16:30**, Acute Coronary Syndromes, Satellite Symposium - Experts on the Spot
Chairpersons: Marc SABATINE

Acute heart failure: new treatment updates  
**Mon 02 Sep, 16:40 - 17:50**, Acute Heart Failure– Treatment, Abstract Session
17:22: Safety and efficacy of sacubitril/valsartan by dose level in patients hospitalized with acute heart failure: Observations from PIONEER-HF, David MORROW
September 03, 2019

Evolving concepts in lipidology

**Tue 03 Sep, 08:30 - 10:00**, Lipids: Drug therapy, Symposium

08:30: LDL: how low should we go? Marc SABATINE

**Prague - Village 2**

Improving cardiovascular risk in patients with obesity

**Tue 03 Sep, 13:00 - 14:00**, Cardiovascular Disease in Special Populations, Satellite Symposium

Chairpersons: Lars RYDEN (Stockholm, Sweden)

13:20: What do we know from cardiovascular outcomes trials in obesity? Erin BOHULA

**Athens - Village 3**

Experts on the spot: exploring new dimensions in glucagon-like peptide-1 receptor agonists and cardiovascular risk

**Tue 03 Sep, 16:00 - 16:30**, Cardiovascular Disease in Special Populations, Satellite Symposium - Experts on the Spot

16:15: Exploring the future role of glucagon-like peptide-1 receptor agonists in cardiovascular disease risk reduction, Benjamin Morgan SCIRICA

**Duras - The Hub**